R‐CHOP plus X regimen or rituximab‐based high‐dose regimen also failed to improve overall survival (OS) for some patients, especially those with MYC and BCL‐2/BCL‐6 double hit/expression, activated B cell (ABC), and CD5‐positive DLBCL.3, 4. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.